A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BIIB037 in Japanese Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BIIB037 in Japanese Subjects With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Aducanumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 12 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 01 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
    • 01 Aug 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top